| Literature DB >> 29468473 |
Aleksandra Ciepłucha1, Olga Trojnarska2, Anna Kociemba3, Magdalena Łanocha2,3, Mikolaj Barczynski2, Szymon Rozmiarek3, Lucyna Kramer4, Malgorzata Pyda2,3.
Abstract
Heart failure and arrhythmia are common complications in adults with Ebstein's anomaly. They may result not only from hemodynamic alterations, but also from myocardial fibrosis. Late gadolinium enhancement (LGE) by CMR enables the evaluation of myocardial fibrosis. The aim of the study was to asses the presence of LGE and its relation to clinical outcome. We studied a group of 37 unoperated adults aged 43.0 ± 14.4 years with Ebstein's anomaly from the congenital heart disease outpatient clinic. Study protocol included: cardiopulmonary test, assessment of supraventricular arrhythmia (SVA), and CMR with evaluation of cardiac chambers' morphology and function, and presence of LGE. Variables following normal distribution were shown as mean ± SD if otherwise median (range) was applied. Fibrosis was found in 18 patients (48.6%) and was distributed as follows: 12 patients (32.4%) in the right atrium, 12 (32.4%) in the atrialized right ventricle, and 2 (5.4%) in the functional right ventricle. In patients with fibrosis, the tricuspid regurgitation fraction was bigger (48.3 ± 19.7 vs. 36.1 ± 22.6%, p = 0.048) and SVA was more frequent [12 (66.7%) vs. 6 (31.6%), p = 0.046] when compared to patients without fibrosis. However, exercise capacity did not differ between patients with and without LGE (peak VO2 24.0 ± 4.7 vs. 23.7 ± 4.4, p = 0.87). In adults with Ebstein's anomaly fibrosis estimated by LGE-CMR was localized in the right atrium and the right ventricle only. Volume overload resulting from tricuspid regurgitation might be a factor conducive to fibrosis. Myocardial fibrosis did not influence exercise capacity. Association between myocardial fibrosis and supraventricular arrhythmia was confirmed.Entities:
Keywords: Congenital heart disease; Ebstein’s anomaly; Exercise capacity; Late gadolinium enhancement; Myocardial fibrosis
Mesh:
Year: 2018 PMID: 29468473 PMCID: PMC6096744 DOI: 10.1007/s00380-018-1141-5
Source DB: PubMed Journal: Heart Vessels ISSN: 0910-8327 Impact factor: 2.037
Fig. 1Cardiac magnetic resonance in patients with Ebstein’s anomaly. a End-diastolic contours of the cardiac chambers: left ventricle (LV), left atrium (LA), functional right ventricle (fRV), and functional right atrium calculated as a sum of atrialized right ventricle (aRV) and anatomical right atrium (RA). Severity index labeled Celermajer index (cmr-Cel) as the ratio of the summed volumes of RA and aRV to that of the summed volumes of fRV, LV, and LA. b Example of a patient with Ebstein’s anomaly without late gadolinium enhancement in the myocardium
Fig. 2Cardiac magnetic resonance in patients with Ebstein’s anomaly. Patient with LGE localized in the functional right atrium in the short-axis view (a) and the four-chamber view (b). Another example of the patient with LGE localized in the functional right atrium in the short-axis view (c) and the four-chamber view (d); yellow arrows indicate LGE
Fig. 3Cardiac magnetic resonance in patients with Ebstein’s anomaly. A schematic division of the functional right atrium into the three main regions. A anterolateral wall, S septal wall, P posterior wall
Clinical characteristics of the whole study population and with regard to the presence of myocardial fibrosis
| Study group ( | LGE (+) subgroup ( | LGE (−) subgroup ( | ||
|---|---|---|---|---|
| Demographic and clinical features | ||||
| Age (years) | 43 (18–76) | 43.0 ± 17.2 | 40.1 ± 11.8 | 0.55 |
| Male ( | 27 (62.8%) | 13 (72.2) | 8 (42.1) | 0.1 |
| BMI (kg/m2) | 25.5 ± 4.6 | 25.0 ± 4.8 | 25.3 ± 4.4 | 0.85 |
| SpO2 (%) | 97.6 ± 0.7 | 97.8 ± 0.6 | 97.5 ± 0.7 | 0.89 |
| HR (bpm) | 77.9 ± 10.8 | 76.8 ± 9.9 | 78.2 ± 10.9 | 0.72 |
| SBP (mmHg) | 120 (90–140) | 120 (110–140) | 120 (90–140) | 0.89 |
| SVA ( | 18 (48.6) | 12 (66.7) | 6 (31.6) | 0.046 |
| Exercise capacity | ||||
| Peak | 23.4 ± 4.5 | 24.0 ± 4.7 | 23.7 ± 4.4 | 0.87 |
| % peak | 65.5 (43.0–114.0) | 65.0 (44.0–114.0) | 66.0 (43.0–88.0) | 0.47 |
| | 32.0 (28–47.5) | 32.0 (28.4–40.0) | 32.0 (28.0–47.5) | 0.42 |
| BNP (pg/ml) | 51.9 (4.5–155) | 65.3 (14.2–155.0) | 37.6 (4.5–134.9) | 0.06 |
| Cardiac magnetic resonance | ||||
| TV displacement (mm/m2) | 17.8 ± 6.3 | 17.3 ± 6.3 | 18.2 ± 6.4 | 0.703 |
| fRV EDV index (ml/m2) | 124.3 (52.8–378.9) | 141.5 (52.8–378.9) | 122.5 (77.4–267) | 0.267 |
| fRV EF (%) | 40.8 ± 11.6 | 38.9 ± 9.8 | 42.7 ± 13.1 | 0.325 |
| aRV EDV index (ml/m2) | 45.9 (10.1–880.9) | 45.9 (15.5–880.9) | 46.7 (10.1–124.6) | 0.558 |
| RA ESV index (ml/m2) | 154.0 ± 144.2 | 196.4 ± 178.0 | 97.7 ± 82.6 | 0.037 |
| fRA EDV index (ml/m2) | 159.5 (65.7–1571.4) | 180.7 (70.8–1571.4) | 122.8 (65.9–456.9) | 0.065 |
| LV EDV index (ml/m2) | 63.7 (38.7–94.2) | 67.6 (38.7–94.2) | 60.4 (50.3–89.5) | 0.242 |
| LV EF (%) | 57.9 ± 8.2 | 55.9 ± 9.2 | 59.9 ± 6.7 | 0.135 |
| LA ESV index (ml/m2) | 33.6 ± 8.3 | 35.8 ± 8.7 | 29.8 ± 10.3 | 0.035 |
| cmr-Cel | 0.7 (0.3–5.3) | 0.8 (0.3–5.3) | 0.6 (0.4–1.4) | 0.15 |
| TR fraction (%) | 41.8 ± 20.7 | 48.3 ± 19.7 | 36.1 ± 22.6 | 0.048 |
LGE late gadolinium enhancement, BMI body mass index, SpO2 blood oxygen saturation, HR heart rate, SBP systolic blood pressure, SVA supraventricular arrhythmia excluding Wollf–Parkinson–White syndrome, peak VO peak oxygen consumption, %peak VO percentage of predicted peak VO2 values, VE/VCO slope ventilation/carbon dioxide slope, BNP brain natriuretic peptide, fRV functional right ventricle, fRA functional right atrium, RA right atrium, aRV atrialized right ventricle, LV left ventricle, cmr-Cel Celermajer index calculated in cardiac magnetic resonance, EF ejection fraction, EDV index end-diastolic volume indexed for body surface area, EDV index end-diastolic volume indexed for body surface area, TV displacement apical displacement of tricuspid septal leaflet indexed by body surface area, TR tricuspid regurgitation
*p value calculated for LGE (+) vs. LGE (−) subgroups
Fig. 4Severity of the tricuspid regurgitation fraction and the extent of myocardial fibrosis within the functional right atrium. A box plot
Fig. 5Distribution of supraventricular arrhythmia among patients with detected fibrosis. Symbols indicating arrhythmia are depicted within the chambers accordingly to the presence of fibrosis and marked white or black color depending on the severity of tricuspid regurgitation. fRA functional right atrium, fRV functional right ventricle, LA left atrium, LV left ventricle; triangle—atrial fibrillation, circle—focal atrial tachycardia, square—reentrant atrial tachycardia, black color—severe tricuspid regurgitation. ns not significant
Factors increasing the probability of LGE presence in patients with Ebstein’s anomaly in a univariable logistic regression analysis
| Parameter | OR | 95% CI |
|
|---|---|---|---|
| Age | 1.014 | 0.97–1.06 | 0.539 |
| Male | 3.575 | 0.86–14.87 | 0.062 |
| TR fraction | 5.378 | 0.19–146.45 | 0.292 |
| fRA ESV index | 1.005 | 0.99–1.011 | 0.058 |
| RA ESV index | 1.016 | 1.01–1.03 | 0.049 |
| aRV ESV index | 1.003 | 0.99–1.01 | 0.319 |
| fRV EDV index | 1.007 | 0.99–1.02 | 0.227 |
| cmr-Cel | 3.381 | 0.54–21.24 | 0.069 |
TR tricuspid regurgitation, fRA functional right atrium, RA right atrium, aRV atrialized right ventricle, fRV functional right ventricle, cmr-Cel Celermajer index calculated in cardiac magnetic resonance, ESV index end-systolic volume indexed to body surface area, EDV index end-diastolic volume indexed for body surface area